These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 708008)

  • 41. Mezlocillin pharmacokinetics in renal impairment.
    Aronoff GR; Sloan RS; Luft FC; Nelson RL; Maxwell DR; Kleit SA
    Clin Pharmacol Ther; 1980 Oct; 28(4):523-8. PubMed ID: 6447570
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Azlocillin and mezlocillin: two new semisynthetic acylureido-penicillins (author's transl)].
    Lode H; Niestrath U; Koeppe P; Langmaack H
    Infection; 1977; 5(3):163-9. PubMed ID: 334673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of piperacillin dose on elimination kinetics in renal impairment.
    Aronoff GR; Sloan RS; Brier ME; Luft FC
    Eur J Clin Pharmacol; 1983; 24(4):543-7. PubMed ID: 6222908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison between the combination of azlocillin-gentamicin and ampicillin-gentamicin in the treatment of a nursery population.
    Fogel D; Farfel L; Miskin A; Mogilner BM
    Isr J Med Sci; 1983 Nov; 19(11):1009-15. PubMed ID: 6662683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of Bay k 4999, a new broad-spectrum penicillin.
    Wise R; Cadge B; Gillett AP; Bhamjee A; Livingston R; Welling PG; Thornhill DP
    Antimicrob Agents Chemother; 1979 May; 15(5):670-3. PubMed ID: 525984
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacokinetics of intravenous mezlocillin in patients with normal and impaired renal function (author's transl)].
    Cano JP; Rigault JP; Gevaudan MJ; Saingra S; Murisasco A; Charpin J
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):335-9. PubMed ID: 6460972
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of piperacillin in subjects with various degrees of renal function.
    Welling PG; Craig WA; Bundtzen RW; Kwok FW; Gerber AU; Madsen PO
    Antimicrob Agents Chemother; 1983 Jun; 23(6):881-7. PubMed ID: 6225390
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function.
    Jungbluth GL; Cooper DL; Doyle GD; Chudzik GM; Jusko WJ
    Antimicrob Agents Chemother; 1986 Dec; 30(6):896-900. PubMed ID: 3492959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Temocillin pharmacokinetics in normal and impaired renal function.
    Höffler D; Koeppe P
    Drugs; 1985; 29 Suppl 5():135-9. PubMed ID: 4029017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function.
    Movin-Osswald G; Boelaert J; Hammarlund-Udenaes M; Nilsson LB
    Br J Clin Pharmacol; 1993 Jun; 35(6):615-22. PubMed ID: 8329289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bone and blood levels of azlocillin after intra-arterial injection in the dog].
    Millart H; Choisy H; Lamiable D; Choisy C
    Presse Med; 1984 Mar; 13(13):802-4. PubMed ID: 6231598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of renal function and dialysis on temocillin pharmacokinetics.
    Boelaert J; Daneels R; Schurgers M; Mellows G; Swaisland AJ; Lambert AM; Van Landuyt HW
    Drugs; 1985; 29 Suppl 5():109-13. PubMed ID: 4029012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment.
    Jungheinrich C; Scharpf R; Wargenau M; Bepperling F; Baron JF
    Anesth Analg; 2002 Sep; 95(3):544-51, table of contents. PubMed ID: 12198032
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin.
    Barriere SL; Catlin DH; Orlando PL; Noe A; Frost RW
    Antimicrob Agents Chemother; 1990 May; 34(5):823-6. PubMed ID: 2360821
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Azlocillin--synovial fluid levels after intravenous doses].
    Härle A; Ritzerfeld W; Wiynck G; Knoche U
    Z Orthop Ihre Grenzgeb; 1983; 121(1):6-9. PubMed ID: 6405553
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients.
    Rouan MC; Binswanger U; Bammatter F; Theobald W; Schoeller JP; Guibert J
    J Antimicrob Chemother; 1984 Jun; 13(6):611-8. PubMed ID: 6088464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.
    Ohkawa M; Orito M; Sugata T; Shimamura M; Sawaki M; Nakashita E; Kuroda K; Sasahara K
    Antimicrob Agents Chemother; 1980 Sep; 18(3):386-9. PubMed ID: 6932824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.